Patent application number | Description | Published |
20080207946 | PROCESS FOR PREPARATION OF HIGHLY PURE ISOTRETINOIN - The present invention relates to a process for preparation of isotretinoin and more specifically, to a purification process for obtaining highly pure isotretinoin that is useful as a keratolytic agent, particularly useful for the treatment of acne. The process involves treating isotretinoin containing metal contamination and/or other impurities with a base in a suitable solvent to form a solution of isotretinoin, followed by adsorption, precipiation, and filtration or centrifugation | 08-28-2008 |
20080261959 | Novel crystalline forms of (S)-N-(1-Carboxy-2-methyl-prop-1-y)-N-pentanoyl-N[2'-(1H-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine - This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and in this connection, to the amorphous form of valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of valsartan. | 10-23-2008 |
20090221715 | NOVEL POLYMORPH OF ATOVAQUONE - The present invention relates to a novel polymorphic form of atovaquone. More particularly, it relates to a novel crystalline form, that has improved solubility and other bulk characteristics suitable for pharmaceutical application. The present invention also relates to processes for preparing a new polymorphic form of atovaquone and its use in industry. | 09-03-2009 |
20100081839 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I - The present invention describes an improved industrial process for crystallizing out polymorph ‘Form I’ of (+) clopidogrel hydrogen sulphate (also called clopidogrel bisulphate) in) from either a Type-1 solvent or liquid characterized by comprising two or more functional groups or their mixtures thereof; or a Type-II solvent and/or solvent mixture selected from the group of methyl ethyl ketone, cyclopentylmethyl ether, dipropylglycolether, dibutylglycol ether, propylmethyl cellosolve, butylmethylcellosolve, propylethylellosolve, butylethylcellosolve or their cross combinations in a reproducible manner without detectable contamination of polymorph designated as ‘Form II’. The invention also discloses improvements in the preparation of clopidogrel free base and process for recovery and recycling of resolving agent camphor sulphonic acid. | 04-01-2010 |
20100081847 | NEW PROCESS FOR PREPARATION OF ATOVAQUONE AND NOVEL INTERMEDIATES THEREOF - Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as “Form IPCA-ATO,” and the preparation thereof. | 04-01-2010 |
20100160635 | INDUSTRIAL PROCESS FOR PREPARATION OF CLOPIDOGREL HYDROGEN SULPHATE - An improved process for the manufacture of Clopidogrel starting from 2-(2-thienyl)ethylamine, which eliminates the isolation of an unstable intermediate like 2-(2-thienyl)ethyl formimine by subjecting it to a one pot cyclization to get 4,5,6,7-tetrahydrothieno (3,2-c) pyridine of Formula II and further reacting with halo-compound of formula III (where X is Cl or Br) at 20 to 90° C. temperature characterized in a solvent like water and/or dichloroethane in presence of organic or inorganic bases is disclosed herein. This inventions also discloses Crystalline Form I of (+)-(S)-clopidogrel hydrogen sulphate and its preparation thereof. | 06-24-2010 |
20110166347 | PROCESS FOR PREPARATION OF MYCOPHENOLIC ACID, ITS SALT AND ESTER DERIVATIVES - The present invention discloses an isolation and purification process for mycophenolic acid obtained from the fermentation process. Invention further discloses preparation of sodium salt of mycophenolic acid and mycophenolate mofetil from mycophenolic acid. | 07-07-2011 |
20120129770 | NOVEL POLYNUCLEOTIDE MOLECULES FOR ENHANCED GENE EXPRESSION - Disclosed herein is an isolated polynucleotide molecule encoding protein such as erythropoietin or structural variants, comprising an expression regulating nucleotide sequence operatively linked to a nucleotide sequence(s) encoding said proteins. The said expression regulatory region comprises of Exon A and at least proximal region of Intron A of Major Immediate Early Region of human Cytomegalovirus or its functional variants which when transfected into host cells results in many fold increase in expression of the protein. | 05-24-2012 |
20120136062 | NOVEL COMPLEX FOR TREATMENT AND/OR PROPHYLAXIS OF PARASITIC INFECTIONS - Disclosed are complexes of an antipneumocystic compound and an antimalarial compound, processes for their preparation, pharmaceutical compositions and methods of using said complexes or compositions for the treatment and/or prophylaxis of parasitic infections. | 05-31-2012 |
20120329762 | ANTI-THROMBOTIC COMPOUNDS - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 12-27-2012 |
20120329763 | ANTI-THROMBOTIC COMPOUNDS - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 12-27-2012 |
20130316986 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 11-28-2013 |
20130316987 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 11-28-2013 |
20140018331 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM - The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided. | 01-16-2014 |
20140031320 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 01-30-2014 |
20140038924 | Anti-Thrombotic Compounds - New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases. | 02-06-2014 |
20150238416 | Pharmaceutical Composition - The present invention relates to a novel pharmaceutical composition having enhanced bioavailability through improved aqueous dissolution of poorly water soluble drugs, and to a method for preparing it. The invention more particularly relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil. | 08-27-2015 |
20150307513 | COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM - The description herein relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the description herein comprises administration of an acyl derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided. | 10-29-2015 |
Patent application number | Description | Published |
20090245115 | METHOD AND SYSTEM FOR PORVIDING HOLISTIC, INTERATIVE, RULE-BASED TRAFFIC MANAGEMENT - An approach is provided for monitoring traffic over a network link that is used to provide one or more services to one or more customers. A determination is made regarding whether a failure mode of the network link has occurred by comparing the monitored traffic to predetermined bandwidth criteria. A corrective action to be taken in response to the failure mode is selected, where selection of the corrective action to be taken is determined based on the failure mode. Further corrective actions selected iteratively from a predetermined list of successive actions are applied until the failure modes are addressed. | 10-01-2009 |
20130074118 | SERVICE ALERT MESSAGES FOR CUSTOMER PREMISES COMMUNICATION DEVICES - A method includes providing identifying information for a customer premises communication device to a provider network, wherein the customer premises communication device is a node of a customer premises network. The method may further include registering a communication channel between the customer premises communication device and the provider network. In addition, the method may include receiving at least one service alert message from the provider network using the communication channel. The type of service alert message is selected based on the customer premises communication device. | 03-21-2013 |
20130179833 | APPLICATION SHORTCUT USER INTERFACE SYSTEMS AND METHODS - An exemplary method includes a user computing device 1) determining current states, such as current integration states and/or current operational states, of software applications included in a suite of software applications relative to the user computing device, 2) identifying, based on the current states, access options for the software applications included in the suite of software applications, and 3) providing, by the user computing device for display, a graphical user interface that includes the access options configured to be selected by a user of the user computing device to access the software applications included in the suite of software applications. Corresponding methods and systems are also disclosed. | 07-11-2013 |
Patent application number | Description | Published |
20090013609 | Polymeric Microgels for Chemical Mechanical Planarization (CMP) Processing - Organic-inorganic composites were prepared as colloidal particles of a cross-linked, thermally responsive polymer. Hybrid PNIPAM-polysiloxane particles and composite polymeric particles with embedded nanoparticles of an inorganic metal-oxide (MO | 01-15-2009 |
20110160089 | DNA Biochip and methods of use - The subject invention concerns materials and methods for detecting nucleic acid sequences. One aspect of the invention concerns a silicon-based “biochip” comprising nucleic acid immobilized thereon. In one embodiment, the silicon comprises microcavities. The nucleic acid to be assayed for the presence of one or more target nucleic acid sequences is immobilized on the silicon. A nucleic acid, such as an oligonucleotide probe, having a sequence substantially complementary to the target nucleic acid sequence can be used to detect the immobilized nucleic acid on the silicon. If the nucleic acid used for detection hybridizes with a target nucleic acid sequence, the hybridized sequences can be detected directly or indirectly. In an exemplified embodiment, the oligonucleotide probe can be labeled with a detectable label, for example, a fluorescent molecule. The subject invention also concerns methods for detecting a target nucleic acid using a silicon-based biochip of the invention. | 06-30-2011 |
20140124021 | MICROSTRUCTURED CRYSTALLINE DEVICE IN CONFINED SPACE, A DYE-SENSITIZED SOLAR CELL, AND METHOD OF PREPARATION THEREOF - A method of forming an ordered nanorods array in a confined space is used to form a high surface area device where an ensemble of parallel trenches has micrometer dimensions for the width and depth of the trenches, which are decorated with crystalline nanowires radiating from the sidewalls and bases of the trenches. The high surface area device is formed by depositing a conformal crystalline seed coating in the trenches, forming microchannels from these trenches by placing a barrier layer on the open surface of the trenches, contacting the conformal coating with a crystal precursor solution that is caused to flow through the microchannels. In an embodiment, a very high surface area electrode is constructed with ZnO nanowires radiating from the sidewalls and base of trenches formed on a silicon substrate. The device can be a dye-sensitized solar cell. | 05-08-2014 |
Patent application number | Description | Published |
20140237995 | SYSTEM, METHOD, AND APPARATUS FOR SULFUR RECOVERY ON AN SCR CATALYST - System, apparatus, and methods are disclosed for treating a reduction catalyst that has been exposed to an amount of sulfur. The treating of the reduction catalyst includes providing a fluid stream at a position upstream of the reduction catalyst. The fluid stream includes a temperature and a reductant amount, and the reductant amount includes an amount of urea, ammonia, or hydrocarbons. | 08-28-2014 |
20140237996 | SYSTEM, METHOD, AND APPARATUS FOR SULFUR RECOVERY ON AN SCR CATALYST - System, apparatus, and methods are disclosed for treating a reduction catalyst that has been exposed to an amount of sulfur. The treating of the reduction catalyst includes providing a fluid stream at a position upstream of the reduction catalyst. The fluid stream includes a temperature and a reductant amount, and the reductant amount includes an amount of urea, ammonia, or hydrocarbons. | 08-28-2014 |
20150113966 | AFTERTREATMENT SYSTEMS WITH REDUCED N2O GENERATION - Systems, apparatus and methods are disclosed for reducing the amount of nitrous oxide (N | 04-30-2015 |
20150354424 | SYSTEM, METHOD, AND APPARATUS FOR IMPROVED DESULFURIZATION OF AFTERTREATMENT COMPONENTS - Systems, methods, and apparatuses are provided for determining an SCR component sulfur value, determining whether the SCR component sulfur value exceeds a sulfur regeneration threshold and increasing an engine NO amount incident to an SCR catalyst in response to the SCR component sulfur value exceeding the sulfur regeneration threshold. | 12-10-2015 |